Skip to main content

Main menu

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions

Asthma: still a promising future?

Pascal Chanez, Marc Humbert
European Respiratory Review 2014 23: 405-407; DOI: 10.1183/09059180.00009614
Pascal Chanez
1Respiratory Medicine APHM, INSERM U1067, Aix-Marseille University, Marseille, France. 2Service de Pneumologie, Université Paris-Sud, AP-HP, Hôpital Bicêtre, Inserm U999, Le Kremlin Bicêtre, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Pascal.chanez@univ-amu.fr
Marc Humbert
1Respiratory Medicine APHM, INSERM U1067, Aix-Marseille University, Marseille, France. 2Service de Pneumologie, Université Paris-Sud, AP-HP, Hôpital Bicêtre, Inserm U999, Le Kremlin Bicêtre, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

To date, asthma remains one of the most frequent chronic diseases in children and adults worldwide [1, 2]. Despite our increased knowledge of the mechanisms and treatments of asthma, we need to better understand the natural history of this lifelong disease. In mild asthma, compliance and adherence to existing and efficient therapies are the main problem whereas in severe asthma, innovative treatments are the new challenges to better control the disease [3–5]. A new series on asthma is, therefore, very welcome in the European Respiratory Review in order to focus on specific areas discussed in recent findings. These series articles, written by expert opinion leaders, can be used to stimulate new ideas as well as provide new forms of management and treatment [6]. The articles deal with hot topics requiring balanced expertise and opinion. The experts will discuss new views on those important questions for researchers and physicians.

The continuing increase in asthma prevalence (more than 400 million cases by 2020) points to a potential role of risk factors. Genetic background is obvious but multiple genes are involved and have been shown to be influenced by environmental factors (epigenetics), even during the gestation period. Lifestyle and environmental exposures are the most commonly studied risk factors. Their role in the inception of asthma is still a matter of debate and despite much research between allergy and asthma the causality between the two has yet to be demonstrated. The hygiene hypothesis is an elegant way to bring together the development of a switch of the immune system and contact with a specific microbial environment. A specific link with nurture is suspected in children with some specific genetic polymorphisms, but again allergy and asthma are not completely discriminated in most studies. The geolocalisation of the subjects (using personal GPS) and the precise environmental exposure to pollutants, allergens and microbes may help to define a more personalised risk to developing the disease [1].

The characteristic mechanisms of asthma include bronchial hyperreactivity, airway inflammation and structural changes of the airways. These different pathways may explain many of the clinical phenotypes, symptoms and exacerbations, and perhaps natural history, of the disease. Eosinophils are key players as the major granulocytes that are recruited, activated and survive within the airway wall, and also migrate to the epithelium lumen [1]. Asthmatic inflammation is associated with an eosinophilic T-helper (Th)2-driven mechanism based on the release of cytokines, such as interleukin (IL)-5, IL-4 and IL-13. This well-established inflammation model is based on various allergic responses requiring an adaptive immune pathway. More recently, it was found that bronchial epithelial cells can communicate with immune cells, such as dendritic cells and innate lymphocytes, though the release of mediators such as thymic stromal lymphopoietin (TSLP), IL-25 or IL-33. This cooperation leads to airway inflammation without a constant need for adaptive immune cell commitment. The respective roles of innate and adaptive immunity requires further clarification, but the role of innate cells in control of eosinophil recruitment is being investigated. Interestingly, both immunity pathways may collaborate to amplify the phenomenon. Bronchial epithelial cells are key in sensing deleterious agents like viruses, allergens or pollutants through specific or nonspecific receptors, such as pathogen-associated molecular patterns, NOD2 or the family of Toll-like receptors. Dendritic cells and innate lymphocytes possess receptors for TSLP. IL-33 and IL-25 can mature and be activated by these pathways leading to the release of cytokines previously considered as Th2 related. Natural killer and type-2 innate lymphoid cells are activated in severe asthma, and have been linked to eosinophilia and the promotion of cytokine release. Lipoxin A4, a mediator derived from the arachidonic metabolism, has been shown to promote the resolution of inflammation linked to innate immunity by inhibiting the in vitro release of IL-13 by type-2 innate lymphoid cells and promoting the apoptosis of eosinophils induced by natural killer cells. Because of the potential defect of lipoxin and other pro-resolution mediators released in severe asthma, hyperactivation of innate immunity may participate in the perpetuation of airway inflammation in these patients, despite current pharmacological treatments [3, 7, 8].

Corticosteroids are still the cornerstone treatment for asthma. In the concordant phenotype, characterised by early onset, usual allergic trigger and eosinophilic bronchial inflammation, low doses of inhaled corticosteroid are usually efficient and safely control the disease. However, if the level of evidence in the literature is high enough to sustain their use as stated in the guidelines, the overall response at a group level is heterogeneous and will depend on the outcomes being studied. The concept of variable corticoresponsiveness is more interesting to investigate than complete corticoresistance, which is rare.

New interventions are currently under development for severe asthma [7, 9–11]. The anti-IL-5 strategy is the most advanced. Findings from proof-of-concept studies in severe asthma with a persistent eosinophilic phenotype, despite high dose of inhaled corticosteroids and long-acting β-agonists therapies, were confirmed in larger multicentre studies. Exacerbation rate and time to first exacerbation were significantly lower in the treated arm compared with the placebo arm in two large studies of mepolizumab [10]. New treatments are emerging for severe asthma, including new anti-IgE therapies and biotherapies against “Th2-high” well-phenotyped patients (anti-IL-13, anti-IL4R/IL-13). Original molecules against epithelium-derived cytokines, such as TSLP and IL-33 or IL-25, are at an early stage but may find their place. Anti-allergic therapies using tablets have been developed to demonstrate efficiency in allergy-driven asthma. We are at the start of a new period when we need to find an organised strategy for the use and combination of these new treatments. Perhaps in the future several lines of biologics will be used subsequently or concomitantly to achieve an optimal control. The major issue remains the cost and the need for the health authorities to compare drugs and evaluate long-term efficacy and safety.

Bronchial thermoplasty is a technique that is available worldwide to treat asthma, and has been approved by several health agencies including the European Medicines Agency and the US Food and Drug Administration [12–14]. It is a new, yet promising treatment for severe asthma. The benefit of long-term asthma control outweighs the short-term risk of deterioration and hospitalisation in the days following treatment according to current literature. However, many questions remain concerning the mechanisms of action of this treatment and many studies are ongoing to find out the optimal responders to bronchial thermoplasty.

Overall, the future for asthma is promising. We are on our way to discovering the roots of the disease with potential for early intervention. New mechanisms have emerged that can provide new biomarkers and focused targets for intervention. It is an important time with drugs that can impact on the natural history of the disease, possibly cure mild asthma, and considerably improve the control and quality of life of the most severe patients. We hope this series in the European Respiratory Review will contribute to reporting this knowledge and provide up-to-date information on this “new deal period” in asthma.

Footnotes

  • Conflict of interest: Disclosures can be found alongside the online version of this article at err.ersjournals.com

  • Provenance: Submitted article, peer reviewed.

  • Received October 13, 2014.
  • Accepted October 14, 2014.
  • ©ERS 2014

ERR articles are open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.

References

  1. ↵
    1. Wenzel SE
    . Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med 2012; 18: 716–725.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Bourdin A,
    2. Molinari N,
    3. Vachier I,
    4. et al
    . Prognostic value of cluster analysis of severe asthma phenotypes. J Allergy Clin Immunol 2014 [In press DOI: 10.1016/j.jaci.2014.04.038].
  3. ↵
    1. Chung KF,
    2. Wenzel SE,
    3. Brozek JL,
    4. et al
    . International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014; 43: 343–373.
    OpenUrlAbstract/FREE Full Text
    1. Humbert M,
    2. Beasley R,
    3. Ayres J,
    4. et al
    . Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005; 60: 309–316.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Deschildre A,
    2. Marguet C,
    3. Salleron J,
    4. et al
    . Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey. Eur Respir J 2013; 42: 1224–1233.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Garcia G,
    2. Taillé C,
    3. Laveneziana P,
    4. et al
    . Anti-interleukin-5 therapy in severe asthma. Eur Respir Rev 2013; 22: 251–257.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Gras D,
    2. Chanez P,
    3. Vachier I,
    4. et al
    . Bronchial epithelium as a target for innovative treatments in asthma. Pharmacol Ther 2013; 140: 290–305.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Barnig C,
    2. Cernadas M,
    3. Dutile S,
    4. et al
    . Lipoxin A4 regulates natural killer cell and type 2 innate lymphoid cell activation in asthma. Sci Transl Med 2013; 5: 174ra26.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Ortega H,
    2. Chupp G,
    3. Bardin P,
    4. et al
    . The role of mepolizumab in atopic and nonatopic severe asthma with persistent eosinophilia. Eur Respir J 2014; 44: 239–241.
    OpenUrlFREE Full Text
  9. ↵
    1. Ortega HG,
    2. Liu MC,
    3. Pavord ID,
    4. et al
    . Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014; 371: 1198–1207.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Moss RB
    . Treatment options in severe fungal asthma and allergic bronchopulmonary aspergillosis. Eur Respir J 2014; 43: 1487–1500.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Iyer VN,
    2. Lim KG
    . Bronchial thermoplasty: reappraising the evidence (or lack thereof). Chest 2014; 146: 17–21.
    OpenUrlCrossRefPubMed
    1. Sheshadri A,
    2. Castro M,
    3. Chen A
    . Bronchial thermoplasty: a novel therapy for severe asthma. Clin Chest Med 2013; 34: 437–444.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Dombret M-C,
    2. Alagha K,
    3. Boulet LP,
    4. et al
    . Bronchial thermoplasty: a new therapeutic option for the treatment of severe, uncontrolled asthma in adults. Eur Respir Rev 2014; 23: 510–518.
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top
View this article with LENS
Vol 23 Issue 134 Table of Contents
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Asthma: still a promising future?
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Asthma: still a promising future?
Pascal Chanez, Marc Humbert
European Respiratory Review Dec 2014, 23 (134) 405-407; DOI: 10.1183/09059180.00009614

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Asthma: still a promising future?
Pascal Chanez, Marc Humbert
European Respiratory Review Dec 2014, 23 (134) 405-407; DOI: 10.1183/09059180.00009614
Reddit logo Technorati logo Twitter logo Connotea logo Facebook logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Asthma and allergy
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Nonpharmacological interventions in COPD
  • The flare of care for rare: per aspera ad astra for rare lung diseases!
  • Respiratory infections
Show more Editorials

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERR

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising
  • Sponsorship

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN: 0905-9180
Online ISSN: 1600-0617

Copyright © 2023 by the European Respiratory Society